Influenza A Virus Hemagglutinin vs Nivolumab
Influenza A Virus Hemagglutinin vs Nivolumab: Overview
This comparison examines the pharmacological differences between Influenza A Virus Hemagglutinin and Nivolumab.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Nivolumab — 27 days.
Chemical Properties
Type: Influenza A Virus Hemagglutinin — Vaccine component; Nivolumab — Antibody.